Juliana M. Chan

Juliana M. Chan

Auto-generated profile, based on publicly available information

Juliana M. Chan

Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2010 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
WGWeiwei Gao
Weiwei Gao
JCJuliana M. Chan
Juliana M. Chan
OFOmid C. Farokhzad
Omid C. Farokhzad

1 March 2009 in Biomaterials
Verified
Journal Article
Closed access
JCJuliana M. Chan
Juliana M. Chan
LZLiangfang Zhang
Liangfang Zhang
KYKai P. Yuet
Kai P. Yuet
GLGrace Liao
Grace Liao
JRJune-Wha Rhee
June-Wha Rhee
OFOmid C. Farokhzad
Omid C. Farokhzad

25 January 2010
Verified
Book Chapter
Closed access
PDF file
JCJuliana M. Chan
Juliana M. Chan
PVPedro M. Valencia
Pedro M. Valencia
LZLiangfang Zhang
Liangfang Zhang
RLRobert Langer
Robert Langer
OFOmid C. Farokhzad
Omid C. Farokhzad

19 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JCJuliana M. Chan
Juliana M. Chan
LZLiangfang Zhang
Liangfang Zhang
RTRong Tong
Rong Tong
DGDebuyati Ghosh
Debuyati Ghosh
WGWeiwei Gao
Weiwei Gao
OFOmid C. Farokhzad
Omid C. Farokhzad
There are a number of challenges associated with designing nanoparticles for medical applications. We define two challenges here: ( i ) conventional targeting against up-regulated cell surface antigens is limited by heterogeneity in expression, and ( ii ) previous studies suggest that the optimal size of nanoparticles designed for systemic delivery is approximately 50–150 nm, yet this size range confers a high surface area-to-volume ratio, which results in fast diffusive drug release. Here, we achieve spatial control by biopanning a phage library to discover materials that target abundant vascular antigens exposed in disease. Next, we achieve temporal control by designing 60-nm hybrid nanoparticles with a lipid shell interface surrounding a polymer core, which is loaded with slow-eluting conjugates of paclitaxel for controlled ester hydrolysis and drug release over approximately 12 days. The nanoparticles inhibited human aortic smooth muscle cell proliferation in vitro and showed greater in vivo vascular retention during percutaneous angioplasty over nontargeted controls. This nanoparticle technology may potentially be used toward the treatment of injured vasculature, a clinical problem of primary importance.

9 July 2008 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
AWAndrew Wang
Andrew Wang
FGFrank Gu
Frank Gu
LZLiangfang Zhang
Liangfang Zhang
JCJuliana M Chan
Juliana M Chan
ARAleksander Radovic-Moreno
Aleksander Radovic-Moreno
OFOmid C Farokhzad
Omid C Farokhzad
Background: The development of nanoparticles for the delivery of therapeutic agents has introduced new opportunities for the improvement of medical treatment. Recent efforts have focused on develop...

15 August 2012 in Annual Review of Biomedical Engineering
Verified
Journal Article
Closed access
KWKeith H.K. Wong
Keith H.K. Wong
JCJuliana M. Chan
Juliana M. Chan
RKRoger D. Kamm
Roger D. Kamm
JTJoe Tien
Joe Tien
In vitro studies of vascular physiology have traditionally relied on cultures of endothelial cells, smooth muscle cells, and pericytes grown on centimeter-scale plates, filters, and flow chambers. The introduction of microfluidic tools has revolutionized the study of vascular physiology by allowing researchers to create physiologically relevant culture models, at the same time greatly reducing the consumption of expensive reagents. By taking advantage of the small dimensions and laminar flow inherent in microfluidic systems, recent studies have created in vitro models that reproduce many features of the in vivo vascular microenvironment with fine spatial and temporal resolution. In this review, we highlight the advantages of microfluidics in four areas: the investigation of hemodynamics on a capillary length scale, the modulation of fluid streams over vascular cells, angiogenesis induced by the exposure of vascular cells to well-defined gradients in growth factors or pressure, and the growth of microvascular networks in biomaterials. Such unique capabilities at the microscale are rapidly advancing the understanding of microcirculatory dynamics, shear responses, and angiogenesis in health and disease as well as the ability to create in vivo–like blood vessels in vitro.